Results

Total Results: over 10,000 records

Showing results for "discussed".

  1. www.ahrq.gov/sites/default/files/wysiwyg/professionals/quality-patient-safety/hais/tools/perinatal-care/modules/teamwork/assemble/assemble-team-facilitator-guide.docx
    May 01, 2017 - Work with team members to consider patient risks identified in the Staff Safety Assessment, which is discussed
  2. effectivehealthcare.ahrq.gov/sites/default/files/pdf/prioritized-research-agenda.pdf
    October 01, 2021 - The Stakeholder 5 Panel discussed the questions and provided feedback through a series of virtual
  3. www.ahrq.gov/sites/default/files/wysiwyg/evidencenow/tools-and-materials/recruitment-and-retention-toolkit.pdf
    January 01, 2019 - Email a follow-up summary following each visit to provide clarity about what was discussed, and as
  4. Obesity (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/obesity-horizon-scan-high-impact-1406.pdf
    June 01, 2014 - management and should not be prescribed for its treatment;” however, results from a 2011 survey (discussed
  5. hcup-us.ahrq.gov/db/nation/nis/APS-DRGsV20DefinitionsManual.pdf
    January 13, 2015 - APS-DRGs® are based upon the SDRG research conducted by CMS, but address the limitations discussed above … Figure 1 illustrates the basic differences in structure for the three systems discussed (CMS DRGs, SDRGs … RESULTS As discussed above, APS-DRGs® were developed as an extension of the proposed CMS SDRG model
  6. hcup-us.ahrq.gov/db/nation/nis/APS-DRGs%20V21%20Definitions%20Manual.pdf
    January 13, 2015 - APS-DRGs® are based upon the SDRG research conducted by CMS, but address the limitations discussed above … Figure 1 illustrates the basic differences in structure for the three systems discussed (CMS DRGs, SDRGs … II.6 RESULTS As discussed above, APS-DRGs® were developed as an extension of the proposed CMS
  7. hcup-us.ahrq.gov/db/nation/nis/reports/2004niscomparisonrpt.jsp
    May 01, 2016 - NIS-MedPAR Evaluations As discussed previously, NIS Medicare discharge estimates were higher than MedPAR … Conclusion Each of the data sources discussed has its strengths and weaknesses, and each may be the … As for which of the data sources discussed is preferable or better, the answer depends on the needs of
  8. effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-guidance-finding-evidence_methods.pdf
    January 01, 2011 - Health Care Program at AHRQ None of the authors has a financial interest in any of the products discussed … Care Program, it does not address searching for previously published systematic reviews, which is discussed … reporting of and more complex search strategies.4-6 Table 1 describes the various search activities discussed
  9. www.ahrq.gov/sites/default/files/wysiwyg/research/findings/making-healthcare-safer/mhs3/ade.pdf
    November 11, 2019 - Practice: Deprescribing To Reduce Polypharmacy in Older Adults 9.2.1 Clinical Outcomes As previously discussed … group (p<0.001).6 Frankenthal et al. (2017) found that when pharmacists and prescribing physicians discussed … related to cognitive declines when medications are reduced and/or eliminated, such findings were not discussed
  10. digital.ahrq.gov/sites/default/files/docs/citation/r21hs024767-yen-final-report-2019.pdf
    January 01, 2019 - When asked to describe factors facilitating or hindering their adaptation to various health IT, nurses discussed … Health IT Usage Nurses also discussed their experiences specifically regarding how various health IT … Participants who hold a leadership role discussed examples of how they monitor usage in order to improve
  11. effectivehealthcare.ahrq.gov/sites/default/files/pdf/kidney-disease-medicine_research-protocol.pdf
    November 01, 2010 - reviewers will attend a training session where the inclusion and exclusion criteria will be presented and discussed … Draft summary tables and figures to be included in the results section of the report will be discussed
  12. www.ahrq.gov/sites/default/files/2024-07/zhou-report.pdf
    January 01, 2024 - Medication Safety We also conducted a narrative review that illustrated the fundamentals of NLP and discussed … frequently reported reactions were more prevalent on social media (i.e., aspirin-induced hypoglycemia was discussed
  13. psnet.ahrq.gov/perspective/conversation-charles-crecelius-md-phd-cmd-and-lori-l-popejoy-phd-rn-faan
    October 28, 2020 - We discussed with them the response to the COVID-19 pandemic in long-term care facilities.    … KH : Is there anything you would like to bring up that we have not discussed
  14. www.ahrq.gov/sites/default/files/wysiwyg/professionals/systems/primary-care/workforce-financing/white_paper.pdf
    January 01, 2020 - Determinants of Health PRAPARE survey, health process and outcome metrics compared by race or SES As discussed … For each of the measures discussed above, the frequency, modality, and approach can greatly influence
  15. www.ahrq.gov/sites/default/files/2025-03/wears-perry-report.pdf
    January 01, 2025 - Results Only the most salient and illustrative results are discussed in this report, in order to keep … An additional risk exists in that the patient may be returned to an abusive situation, as discussed
  16. www.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/chipra-88-measure-1-section-14-attachment-1.pdf
    January 01, 2011 - We also discussed creating an outcome measure on symptom reduction but the work group was limited to … Additionally, we discussed forming a measure on prescribing first line therapy for children other than
  17. www.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/chipra-89-adhd-behavior-section-14-attach-1.pdf
    January 01, 2011 - We also discussed creating an outcome measure on symptom reduction but the work group was limited to … Additionally, we discussed forming a measure on prescribing first line therapy for children other than
  18. www.uspreventiveservicestaskforce.org/home/getfilebytoken/vmHooQ6ABG9CagdUXv2_rx
    August 25, 2021 - transient eleva- tions in liver enzyme or creatine kinase levels is unknown.1,17 In the statin trials discussed … that there were no adverse events.1,17 Multifactorial Dyslipidemia The 2 behavioral counseling trials discussed
  19. www.ahrq.gov/research/findings/final-reports/crcscreeningrpt/crcscreen3.html
    April 01, 2018 - intervention evaluation study, practices and patients had to meet the inclusion/exclusion criteria discussed … During our informal conversation with LVHN project staff, we discussed the following topics: How
  20. psnet.ahrq.gov/perspective/long-term-care-and-response-covid-19
    October 28, 2020 - We discussed with them the response to the COVID-19 pandemic in long-term care facilities.    … KH : Is there anything you would like to bring up that we have not discussed